

BioRN Lounge with: Jürgen Gamer, [Apogenix AG](#)

Topic: *“TNF Superfamily Receptor Modulators – Innovative Immunology Therapeutics”*

June 26, 2018, 7pm

At the restaurant Urban Kitchen, Poststr. 36/5 in Heidelberg

Register by emailing to Sibylle Geilenberg: sg@biorn.org



Dr. Jürgen Gamer

About:

Apogenix will present data on its innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising [pipeline](#) of drug candidates that target different [TNFSF](#)-dependent signaling pathways, thereby restoring the anti-tumor immune response. The presentation will focus on Apogenix' lead immuno-oncology candidate [asunercept \(APG101\)](#) which has been awarded PRIME (PRiority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of glioblastoma. The program focuses on medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options and enables accelerated assessment of marketing applications.

Speaker: Dr. Jürgen Gamer, VP Business Development, [Apogenix AG](#)

Juergen Gamer joined Apogenix AG as VP, Business Development in January 2006 responsible for partnering and licensing activities. Throughout his career, Juergen built a successful track record of transactions including alliances, licensing, and M&A agreements with major pharmaceutical and biotechnology companies in the US, Europe, and China. He is also member of the strategic advisory board of BioRN, one of the leading biotech clusters in Europe.

From 2000 to 2005 he worked for Graffinity AG / Santhera Pharmaceuticals AG as VP, Business Development and Project Management acquiring deals and leading alliance management. In the years from 1998 to 2000 Jürgen Gamer served at Clontech Lab. Inc., USA as Head of Business Development Europe where he was responsible for the licensing business in Europe. His industrial career started at BASF Pharma from 1995 to 1998 in the life science department. He obtained his Ph.D. in 1995 with highest honors from the “Zentrum für Molekulare Biologie” Heidelberg (ZMBH) at the University of Heidelberg.